The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models

The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) Vol. 138; p. S53
Main Authors: Munck, J., Berdini, V., Courtin, A., East, C., Heightman, T., Hindley, C., Kucia-Tran, J., Lyons, J., Martins, V., Muench, S., Murray, C., Norton, D., O’Reilly, M., Reader, M., Rees, D., Rich, S., Thompson, N., Wilsher, N., Woolford, A., Wallis, N.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(20)31218-1